Suppr超能文献

国家基本药物目录(2015 年版)与世界卫生组织基本药物标准清单(第 19 版)的比较分析。

Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition).

机构信息

Suqian People's Hospital of Nanjing Drum-Tower Hospital Group, Suqian 223800, China.

Affiliated Suqian Hospital of Xuzhou Medical University, Suqian 223800, China.

出版信息

Biomed Res Int. 2018 Jun 10;2018:7862306. doi: 10.1155/2018/7862306. eCollection 2018.

Abstract

OBJECTIVE

To explore the safety of the essential medicines recorded in China's list through the comparison of the list of essential medicines of China and the World Health Organization (WHO), as well as the analysis of the basic situation and characteristics of adverse drug reactions (ADRs) on the two essential medicines recorded in China's and WHO lists in order to provide a reference for the improvement of China's list.

METHODS

A retrospective descriptive study was conducted, based on the database in Jiangsu Province ADR Monitoring Center from 2013 to 2015. A total of 266869 cases reports were collected within this period, comparing the differences between the two essential medicines recorded in China's and WHO lists, considering number of ADRs, type of report, and modes of administration. Compare the differences between the two groups of drugs in the presence of new, severe, and new severe adverse events using chi square test.

RESULTS

Comparing the two essential medicines list, they have the same 117 species. When comparing ADRs in the two groups, most are antimicrobial, electrolytes, and acid-base balance drugs, regulate water, and are higher in China. In addition, with respect to the number of ADR types in the two groups, there is statistical significance (p<0.001) (total number is 68603 and 47515, new types are 12601 and 7262, the severe are 2714 and 7566, and the new severe are 820 and 716).

CONCLUSION

Compared to the WHO list of essential drugs, China's list is still to be improved.

摘要

目的

通过对比中国和世界卫生组织(WHO)的基本药物目录,分析中国和 WHO 基本药物目录中收录的药品不良反应(ADR)基本情况和特点,探讨中国目录收录药品的安全性。

方法

采用回顾性描述性研究方法,利用江苏省药品不良反应监测中心 2013 年至 2015 年的数据库,收集共 266869 例报告,比较中国和 WHO 基本药物目录中收录药品的差异,从 ADR 数量、报告类型、给药途径等方面进行分析。采用卡方检验比较两组新的、严重的、新的严重 ADR 事件的差异。

结果

比较中国和 WHO 基本药物目录,收录的品种完全相同有 117 种。比较两组 ADR 报告,均以抗感染药、电解质和酸碱平衡药物、调节水、电解质及酸碱平衡药物为主,且中国 ADR 报告数量高于 WHO。另外,两组 ADR 报告类型数量比较,差异有统计学意义(p<0.001)(总数分别为 68603 例和 47515 例,新的 ADR 类型分别为 12601 例和 7262 例,严重的 ADR 类型分别为 2714 例和 7566 例,新的严重的 ADR 类型分别为 820 例和 716 例)。

结论

与 WHO 基本药物目录相比,中国目录还需进一步完善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6abe/6015697/fe97753ddd34/BMRI2018-7862306.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验